Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
We examined the effect of intravenously infused glucagon-like peptide 1 (GLP-1) on subjective appetite sensations after an energy-fixed breakfast, and on spontaneous energy intake at an ad libitum lunch. 20 young, healthy, normal-weight men participated in a placebo-controlled, randomized, blinded, crossover study. Infusion (GLP-1, 50 pmol/ kg.h or saline) was started simultaneously with initiation of the test meals. Visual analogue scales were used to assess appetite sensations throughout the experiment and the palatability of the test meals. Blood was sampled throughout the day for analysis of plasma hormone and substrate levels. After the energy-fixed breakfast, GLP-1 infusion enhanced satiety and fullness compared with placebo (treatment effect: P < 0.03). Furthermore, spontaneous energy intake at the ad libitum lunch was reduced by 12% by GLP-1 infusion compared with saline (P = 0.002). Plasma GLP-1, insulin, glucagon, and blood glucose profiles were affected significantly by the treatment (P < 0.002). In conclusion, the results show that GLP-1 enhanced satiety and reduced energy intake and thus may play a physiological regulatory role in controlling appetite and energy intake in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RA increase satiety, reduce food intake and delay gastric emptying whilst they also stimulate insulin release and inhibit glucagon secretion in a glucose-dependent manner (Fig. 1) [17, 18].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Short-term studies have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RA) induce weight loss by promoting satiety and reducing hunger16–19.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, non-clinical and clinical studies have demonstrated increased satiety, reduced food intake and subsequent reductions in body weight following administration of GLP-1,7, 8”
From Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults (2014) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [3]
In the citing paper
“GLP-1 receptor agonists (GLP-1RA) have been shown to promote weight loss and decrease liver fat [28,29] (Figure 1).”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [29]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 19,795
(1974) · Elsevier eBooks · doi:10.1016/b978-0-12-091304-6.x5001-0 · Cited by 6,755
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Cited by
Items 901–1,000 of 1,003
Gut–brain communication: how does it stand after bariatric surgery?
Diniz, M. D. F. H. S., Passos, V. M. D. A., & Diniz, M. T. C. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000241676.63041.11 · Cited by 13
Østergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
“A few years later, other groups also showed that GLP-1 promotes weight loss by reducing appetite and delaying gastric emptying [33–35].”
Patil, M., Casari, I., Warne, L. N., & Falasca, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116245 · Cited by 12
Incretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
“More - over, the subjects with obesity and T2DM receiving GLP-1 analogs exerted metabolic and appetite responses comparable to healthy individuals [ 16 , 66–69 ].”
Avilés-Olmos, I., Espinoza‐Vinces, C., Portugal, L. R., & Luquin, M. R. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01606-1 · Cited by 13
“Peripherally, they reduce insulin resistance, slow gastric emptying and promote weight loss, which is ben - eficial for T2D but potentially problematic in PD [ 12, 13 ].”
InfluentialNo Change in Serum Incretins Levels but Rise of Leptin Levels After Smoking Cessation: a Pilot Study
Pánková, A., Králíková, E., Kaválková, P., STEPANKOVA, L., Zvolská, K., & Haluzík, M. (2016) · Physiological Research · doi:10.33549/physiolres.933154 · Cited by 12
“…2011) as well as lipid metabolism (Meier et al. 2006, Phillips and Prins 2011, Zinman et al. 2009), gut motility (Campbell and Drucker 2013), appetite and body weight (Flint et al. 1998, Flint et al. 2000, Dirsen et al. 2012, Verdich et al. 2001), and immune function (Campbell and Drucker 2013).”
Backgroundvan Olst, N., Meiring, S., de Brauw, M., Bergman, J. J. G. H. M., Nieuwdorp, M., van der Peet, D. L., & Gerdes, V. E. A. (2020) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2020.03.003 · Cited by 13
Men, P., Qu, S., Song, Z., Liu, Y., Li, C., & Zhai, S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00857-3 · Cited by 12
“GLP-1 RAs, such as lixisenatide, can promote satiety and suppress energy intake and thus have a significant beneficial value in terms of weight control compared with insulins [36].”
BackgroundCamacho, R. C., You, S.-H., D’Aquino, K. E., Li, W., Wang, Y., Gunnet, J. W., Littrell, J. B., Qi, J. S., Kang, L., Jian, W., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1794687 · Cited by 13
“The incretin hormone glucagon-like peptide 1 (GLP1), and activation of its receptor (GLP-1R), have an array of beneficial effects in glucose metabolism and energy balance in humans, including stimulation of glucose-dependent insulin secretion,(1) as well as inhibiting glucagon secretion,(2) gastric emptying,(3) and fo…”
BackgroundIncreasing clinical awareness of obesity as a serious, chronic, relapsing, and treatable disease
Lazarus, E. (2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89290 · Cited by 12
Cruciani, S., Delitala, A., Cossu, M. L., Ventura, C., & Maioli, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032310 · Cited by 19
Dumiaty, Y., Underwood, B., Phy-Lim, J., & Chee, M. J. (2024) · Neuropeptides · doi:10.1016/j.npep.2024.102427 · Cited by 9
“In humans, acute intravenous administration of synthetic GLP-1 reduced meal size in normal-weight individuals (Flint et al., 1998) and those with obesity (Flint et al., 2001; N ¨ aslund et al., 1999; Verdich et al., 2001).”
BackgroundNauck, M. A., & Vardarli, I. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00004.x · Cited by 12
Wadikar, D. D., & Premavalli, K. S. (2012) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2010.514757 · Cited by 19
Tight control of hyperglycemia in type 2 diabetes mellitus
Donner, T. W. (2006) · Insulin · doi:10.1016/s1557-0843(06)80037-0 · Cited by 12
Review of approved pioglitazone combinations for type 2 diabetes
Forst, T. M., Hanefeld, M., & Pfützner, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.567266 · Cited by 12
“While GIP seemed to be less effective in T2DM, the actions of GLP-1 include the glucose-dependent release of insulin from the beta cell, a glucose-dependent suppression of glucagon secretion, slowing of gastric emptying, promotion of satiety and an improvement in beta-cell function [127,128].”
BackgroundFiber intake Inconsistently Alters Gut Hormone Levels in Humans Following Acute or Chronic Intake
Klosterbuer, A. S., Greaves, K. A., & Slavin, J. L. (2012) · Journal of Food Research · doi:10.5539/jfr.v1n2p255 · Cited by 13
Brown, E. E., Wilton, M., Sprung, V. S., Harrold, J. A., Halford, J. C. G., Stančák, A., Burgess, M. I., Howarth, E., Umpleby, A. M., Kemp, G. J., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045663 · Cited by 13
Treatment of type 2 diabetes in children: what are the specific considerations?
Grøndahl, M. F. G., Johannesen, J., Kristensen, K., & Knop, F. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1954160 · Cited by 13
Hormone-based therapies in the regulation of fuel metabolism and body weight
Kesty, N. C., Roth, J. D., & Maggs, D. G. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.11.1733 · Cited by 13
“In clinical studies, continuous infusion of GLP-1 reduced food intake and increased satiety in both lean and obese individuals [74-76] , and a meta-analysis of human GLP-1 studies demonstrated that peripherally-administered GLP-1 reduced food intake by ∼ 12% [77] .”
BackgroundÜçkaya, G., Delagrange, P., Chavanieu, A., Grassy, G., Berthault, M., Ktorza, A., Cerasi, E., Leibowitz, G., & Kaiser, Ν. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.05818 · Cited by 12
Management of Obesity in Adults
SKOLNIK, N., & Ryan, D. H. (2014) · Cited by 12
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Viljoen, A., & Bain, S. C. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1642 · Cited by 11
“The same group showed that GLP1 inhibited gastric and exocrine pancreatic secretion [10] and also that infusing GLP1 in humans inhibited appetite and food intake [11].”
Hengist, A., Sciarrillo, C. M., Guo, J., Walter, M. F., & Hall, K. D. (2024) · Obesity · doi:10.1002/oby.24104 · Cited by 13
“Supraphysiological concentrations of GLP-1 achieved by infusion ( (cid:1) 25 – 30 pg/mL) suppress subjective appetite, but effects on subsequent ad libitum energy intake are modest compared with higher concentrations ( (cid:1) 100 – 240 kcal) [46, 47].”
Dagbasi, A., Fuller, A., Hanyaloglu, A. C., Carroll, B., McLaughlin, J. T., Frost, G. S., & Holliday, A. (2024) · Appetite · doi:10.1016/j.appet.2024.107718 · Cited by 13
“, glucagon like peptide-1 (GLP-1 (Flint, Raben, Astrup, & Holst, 1998);)”
Homoródi, N., Varga, É., Szabó, Z., Sztanek, F., & Harangi, M. (2025) · Biomedicines · doi:10.3390/biomedicines13112595 · Cited by 15
“In the heart, GLP-1 is expressed in both atrial and ventricular tissues, including the sinoatrial node [14,16], and the presence of its receptors has also been detected on the surface of endothelial cells in blood vessels [17].”
Gao, M., Tian, H., Ma, C., Gao, X., Guo, W. Y., & Yao, W. (2009) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-009-8725-6 · Cited by 11
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Davidson, J. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1096743 · Cited by 12
“GLP-1 can also reduce food intake both by mediating a key role in satiation and by inhibiting gastric emptying [7,8].”
BackgroundHuang, T., Wang, G., Shahbazi, M., Bai, Y., Zhang, J., Feng, G., Asadian, E., Ghorbani-Bidkorpeh, F., Yang, Z., Li, Y., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202210627 · Cited by 11
Ciccarelli, G., Giuseppe, G. D., Cinti, F., Moffa, S., Mezza, T., & Giaccari, A. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3668 · Cited by 11
“75 In conclusion, weight loss—due to a reduction in caloric intake ‐”
Mody, R., Valentine, W. J., Hoog, M. M., Sharland, H., & Belger, M. A. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.2.153 · Cited by 13
Update on Pediatric Anti-obesity Medications—Current Landscape and Approach to Prescribing
Ahn, Y. J., Maya, J., & Singhal, V. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00566-z · Cited by 12
Hellström, P. M., Smithson, A., Stowell, G. W., Greene, S. F., Kenny, E., D'Amico, C., Leone‐Bay, A., Baughman, R., GRANT, M. L., & Richardson, P. C. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.08.009 · Cited by 11
Comparison of Capsaicin and Capsiate’s Effects at a Meal
Swint, J. M., Beining, K. M., Bryant, J. A., Tucker, R. M., & Ludy, M. (2015) · Chemosensory Perception · doi:10.1007/s12078-015-9188-5 · Cited by 13
Early clinical studies with liraglutide
Schmidt, W. E. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02500.x · Cited by 13
Rigamonti, A. E., Bini, S., Grugni, G., Agosti, F., Col, A. D., Mallone, M., Cella, S. G., & Sartório, A. (2013) · Clinical Endocrinology · doi:10.1111/cen.12395 · Cited by 14
Liraglutide: A once-daily human glucagon-like peptide-1 analogue
Aimaretti, G. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345744 · Cited by 11
Milton, J. E., Sananthanan, C. S., Patterson, M., Ghatei, M. A., Bloom, S. R., & Frost, G. S. (2007) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602654 · Cited by 11
Schwartz, S. S. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802390795 · Cited by 11
Aspectos fisiológicos do balanço energético
Mancini, M. C., & Halpern, A. (2002) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302002000300005 · Cited by 16
Garber, A. J. (2015) · Endocrine Practice · doi:10.4158/ep14460.ra · Cited by 12
Schwanstecher, C., & Schwanstecher, M. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_1 · Cited by 13
“In patients with T2DM, GLP-1 was demonstrated to enhance glucose-dependent insulin secretion, normalize glucagon release, slow gastric emptying, diminish food intake and induce weight loss, thus suggesting significant therapeutic potential (Deacon et al. 1995b; Flint et al. 1998; Zander et al. 2002; Nauck and Meier 20…”
BackgroundKhan, M. I., & Weinstock, R. S. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0974-2.00016-6 · Cited by 28
Gastrointestinal peptides after bariatric surgery and appetite control: are they in tuning?
Doucet, É. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32830ab9c9 · Cited by 13
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
LEAP2 as a therapeutic target in obesity and cardiometabolic disorders
Holm, S. K., Johansen, V. B. I., & Clemmensen, C. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-10007-4 · Cited by 11
“Notably, infusion of a native LEAP2 peptide in healthy men, reaching supraphysiological concentrations, reduced food intake to a similar extent as native GLP-1 following acute infusion [34, 141].”
Singh, A., & Nissen, S. E. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0122 · Cited by 11
“20 Research subsequently shifted to the GLP-1R receptor as a therapeutic target, opening the door for an entirely new class of medications.”
Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
Basile, L., Cannarella, R., Iuliano, S., Calogero, A. E., Condorelli, R. A., Greco, E. A., Aversa, A., & Vignera, S. L. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04103-9 · Cited by 11
Fat sensing and metabolic syndrome
Youn, J. H. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9300-1 · Cited by 12
Rieger, T. R., & Musante, C. J. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.05.006 · Cited by 10
The role of glucagon‑like peptide 1 in glucose homeostasis and in other aspects of human physiology
Franek, E., Gajos, G., Gumprecht, J., Kretowski, A. J., Zahorska‐Markiewicz, B., & Malecki, M. T. (2009) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.829 · Cited by 14
Byrne, C., Blunt, D. M., Burn, J., Chambers, E. S., Dagbasi, A., Becker, G. F., Gibson, G. R., Mendoza, L. C., Murphy, K. G., Poveda, C. G., et al. (2019) · F1000Research · doi:10.12688/f1000research.17870.2 · Cited by 10
Hunt, J. E., Holst, J. J., & Jepsen, S. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.884501 · Cited by 12
“98170-4), and (125)I-labeled human GIP(1-42) tracer (cat.”
MethodSelf-citationAl‐Zaid, B., Chacko, S., Ezeamuzie, C. I., Bünemann, M., Krasel, C., Karimian, T., Lanzerstorfer, P., & Al‐Sabah, S. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1013 · Cited by 10
Psychobiological mechanisms in food choice
Yeomans, M. R. (2007) · Elsevier eBooks · doi:10.1533/9781845693381.1.81 · Cited by 11
Kawata, T. (2014) · Journal of Clinical Medicine Research · doi:10.14740/jocmr1719w · Cited by 10
“GLP-1 receptor agonists, in addition to acting to improve blood glucose, control appetite [1], promote regeneration and proliferation of pancreatic β cells, and have extrapancreatic actions such as inhibiting apoptosis [2, 3].”
BackgroundChen, J., Bai, G., Cao, Y., Gao, Z., ZHANG, Q., Zhu, Y., & Yang, W. (2007) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.70190 · Cited by 10
Meessen, E. C. E., Bakker, G. J., Nieuwdorp, M., Dallinga‐Thie, G. M., Kemper, E. M., Damink, S. W. M. O., Romijn, J. A., Hartmann, B., Holst, J. J., Knop, F. K., et al. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.06.032 · Cited by 11
Self-citationIncretin-based Therapy in Chronic Kidney Disease
Pinelli, N. R., Moore, C. L., & Tomasello, S. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.06.003 · Cited by 13
Signals Arising from the Gastrointestinal Tract that Affect Food Intake
Purhonen, A. (2008) · Cited by 10
Towards a translational approach to food addiction: Implications for bulimia nervosa
Leslie, M., Lambert, E., & Treasure, J. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00264-0 · Cited by 9
Bauer, I., Rimbach, G. H., Cordeiro, S., Bosy‐Westphal, A., Weghuber, J., Ipharraguerre, I. R., & Lüersen, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1396292 · Cited by 10
“Subsequently,GLP-1elicitspleiotropiceffectsonthetargetorganssuchasthepancreas(Mojsovetal.,1987;Ramracheyaetal.,2018), brain(Flintetal.,1998;Perryetal.,2002),gastrointestinal(GI)tract(Tolessaetal.,1998;Chelikanietal.,2005),orheart(Barragánetal.,1994;Readetal., 2012; McCormick et al., 2015).”
Taylor, D., Pittenger, G. L., & Vinik, A. I. (2008) · Drug Development Research · doi:10.1002/ddr.20242 · Cited by 9
Modulating of food glycemic response by lactic acid bacteria
Mutlu, C., Candal, C., ÖZHANLI, H., Arslan‐Tontul, S., & Erbaş, M. (2022) · Food Bioscience · doi:10.1016/j.fbio.2022.101685 · Cited by 9
In vitro cell cultures of Brunner’s glands from male mouse to study GLP-1 receptor function
Voetmann, L. M., Underwood, C. R., Rolin, B., Hansen, A. K., Kirk, R. K., Pyke, C., Knudsen, L. B., & Frederiksen, K. S. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00345.2021 · Cited by 10
Davies, I., & Tan, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2203911 · Cited by 10
“In addition to this, GLP-1 also has an appetite suppressive effect in animals [7] and in man [8], possibly mediated by GLP-1 receptor expressing neurones in the hypothalamus, known to be important for appetite regulation [9].”
BackgroundKamemoto, K., Tataka, Y., Hiratsu, A., Nagayama, C., Hamada, Y., Kurata, K., Chiyoda, M., Ito, M., & Miyashita, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-58103-w · Cited by 12
“Furthermore, GLP-1 has anorexigenic effects and reduces food intake 27 although this was not examined in the present study.”
BackgroundFujiwara, Y., Yamane, S., Harada, N., Ikeguchi, E., Usui, R., Nakamura, T., Iwasaki, K., Suzuki, K., Yabe, D., Hayashi, Y., et al. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00312.2020 · Cited by 9
Lin, J. J., Yang, D., Ou, S. J. L., Mak, Y. Y., Lee, D. P. S., Lim, K. L., Tai, E. S., Liu, M. H., & Khan, S. A. (2022) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2022.107544 · Cited by 9
Liraglutide: a human GLP-1 analog for Type 2 diabetes
Vilsbøll, T. (2009) · Therapy · doi:10.2217/14750708.6.2.199 · Cited by 10
Fetissov, S. O., Meguid, M. M., Shafiroff, M., Miyata, G., & Torelli, G. F. (2000) · Nutrition · doi:10.1016/s0899-9007(99)00205-1 · Cited by 9
Emerging role of insulin with incretin therapies for management of type 2 diabetes
Ahluwalia, R., & Vora, J. P. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0005-0 · Cited by 10
Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs
Efendić, S., Alvarsson, M., Brismar, K., & Wagner, H. (2007) · Acta Physiologica · doi:10.1111/j.1748-1716.2007.01789.x · Cited by 10
Glycemic response to low sugar apple juice treated with invertase, glucose oxidase and catalase
Laue, C., Ballance, S., Knutsen, S. H., Papazova, E., Soeth, E., Pannenbeckers, A., & Schrezenmeir, J. (2019) · European Journal of Clinical Nutrition · doi:10.1038/s41430-019-0421-1 · Cited by 9
Lin, F., Chen, H., Liu, J., Gao, Y., Zhang, X., Hao, J., Chen, D., Wu, H., Yuan, D., Wang, T., et al. (2015) · Aquaculture · doi:10.1016/j.aquaculture.2015.06.014 · Cited by 9
Gastric Emptying Controls Type 2 Diabetes Mellitus
Mason, E. E. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9196-x · Cited by 9
The unexpected role of GIP in transforming obesity treatment
Zandvakili, I., & Pérez–Tilve, D. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.022 · Cited by 9
Alluri, A. A., Guntupalli, Y., Suvarna, S. S., Prystupa, Y., Khetan, S. P., Vejandla, B., & Swathi, N. L. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0031 · Cited by 11
Mukherjee, A., DiBrog, A. M., & Mietlicki‐Baase, E. G. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113869 · Cited by 8
Correia, A. S., Pereira, S., Morais, T., Martins, A. D., Monteiro, M. P., Alves, M. G., & Oliveira, P. F. (2022) · Biomedicines · doi:10.3390/biomedicines10102609 · Cited by 8
“Interventions such as GLP-1 analogs administration and CR can lead to a negative energy balance status [29,30].”
BackgroundFediuk, D. J., Gorman, D. N., Stoddard, S., Zhang, Y., Ogden, A. G., Winton, J. A., & Saxena, A. R. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2371 · Cited by 8
Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management
Rabbani, S. A., El‐Tanani, M., Matalka, I. I., Rangraze, I. R., Aljabali, A. A. A., Khan, M. A., & Tambuwala, M. M. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2395540 · Cited by 9
“Notably, exogenous infusion of GLP-1 triggers various glucose-reducing effects, including promoting insulin release after glucose ingestion, hampering gastric emptying, and decreasing glucagon secretion in both normal and T2D subjects [56].”
Hunting for heroes: Brain neurons mediating GLP-1R agonists in obesity treatment
Cao, Y., & Tong, Q. (2024) · Obesity Medicine · doi:10.1016/j.obmed.2024.100569 · Cited by 10
Can Bayliss and Starling gut hormones cure a worldwide pandemic?
Scott, R., Tan, T., & Bloom, S. R. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.272955 · Cited by 10
“Jens Holst’s groupadministered GLP-1 via a subcutaneous infusion to both lean and obese human subjects, and demonstrated an increase in the sensation of satiety, a reduction in the sensation of hunger, and a reduction in caloric intake at a subsequent meal (Flint et al. 1998; Näslund et al. 1999).”
No effects of Korean pine nut triacylglycerol on satiety and energy intake
Verhoef, S. P. M., & Westerterp, K. R. (2011) · Nutrition & Metabolism · doi:10.1186/1743-7075-8-79 · Cited by 9
“Both CCK and GLP-1 have shown to be involved in the development of satiation, by suppressing appetite and energy intake [2-5].”
BackgroundWełnicki, M. T., Gorczyca-Głowacka, I., Mamcarz, A., Filipiak, K. J., Wożakowska−Kapłon, B., Barylski, M., Szymański, F. M., Kasprzak, J. D., Grabowski, M., & Dzida, G. J. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0282 · Cited by 15
Stabilizing effect of exenatide in a patient with C‐peptide‐negative diabetes mellitus
Paisley, A. N., Savage, M. W., & Wiles, P. G. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02789.x · Cited by 8
Yoon, S. B., Choi, M., Lim, C., Kim, J. S., Cho, Y. K., Park, J. M., Lee, I. S., Kim, S. W., Choi, K. Y., & Chung, I. (2012) · Digestion · doi:10.1159/000335933 · Cited by 8
Singh‐Franco, D. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1004311 · Cited by 12
“Other plausible effects of GLP-1 that contribute to glucose lowering include suppression of glucagon secretion in islet a-cells [8], delayed gastric emptying [9,10] and induction of satiety (FIGURE 1A) [7,11].”
BackgroundRotondo, A., Masuy, I., Verbeure, W., Biesiekierski, J. R., Deloose, E., & Tack, J. F. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15195 · Cited by 11
“It is also known as an anorexigenic peptide that increases satiety.(5,6) Additionally, GLP‐1 acts as a mediator of the ileal brake,(7) reduces gut motility,(8,9) increases gastric accommodation,(10,11) slows gastric emptying(12) and inhibits gastric acid secretion.”
BackgroundKoyuncu, B. Ü. (2014) · Cited by 8
Influence of gestational age on serum incretin levels in preterm infants
Shoji, H., Watanabe, A., Ikeda, N., Mori, M., Kitamura, T., Hisata, K., & Shimizu, T. (2016) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174416000404 · Cited by 8
Glucagon-like peptide 1 (GLP-1) and incretin mimetics for the treatment of diabetes
Nauck, M. A. (2005) · Practical Diabetes · doi:10.1002/pdi.801 · Cited by 8
Growth Hormone and Body Composition
Mersebach, H., & Feldt‐Rasmussen, U. (2005) · KARGER eBooks · doi:10.1159/000088423 · Cited by 8
The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist
Christensen, M., Knop, F. K., & Vilsbøll, T. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.30 · Cited by 7
Hypothalamic GPCR Signaling Pathways in Cardiometabolic Control
Deng, Y., Deng, G., Grobe, J. L., & Cui, H. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.691226 · Cited by 8
Yeomans, M. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-14504-0_30 · Cited by 9
Zheng, W., Duan, H., Cao, L., Mao, S., & Shen, J. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1381871 · Cited by 7
“Both GLP-1 and PYY serve as satiety signals that can reduce animal feed intake by modulating intestinal movement and increasing bodily satiety (43, 44).”
BackgroundAn insoluble cellulose nanofiber with robust expansion capacity protects against obesity
Yu, J. G., Gao, M., Wang, L., Guo, X., Liu, X., Sheng, M., Cheng, S., Guo, Y., Wang, J., Zhao, C., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134401 · Cited by 9
Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists
Cook, T. M., Fuller, K. N. Z., & Sandoval, D. A. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110269 · Cited by 7
Metadata
- Authors
- Flint, A., Raben, A., Astrup, A., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-01
- Volume
- 101
- Issue
- 3
- Pages
- 515-520
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508592
- OpenAlex
- W1975756049
- Cited by
- 1,402
- References
- 40
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 62 · 2023: 33 · 2022: 55 · 2021: 53 · 2020: 49 · 2019: 44 · 2018: 52 · 2017: 49 · 2016: 54 · 2015: 59 · 2014: 64 · 2013: 74 · 2012: 72
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, satiety, appetite, energy intake, insulin, glucagon, blood glucose, appetite regulation, intravenous infusion
- MeSH terms
- Adult, Appetite, Appetite Depressants, Appetite Regulation, Blood Glucose, Energy Intake, Glucagon, Humans, Insulin, Male, Pain Measurement, Peptide Fragments, Protein Precursors, Satiation, Cross-Over Studies, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.